The role of the purinergic ligand-gated ion channel 7 receptor in common digestive system cancers.

IF 2.1 4区医学 Q3 ONCOLOGY European Journal of Cancer Prevention Pub Date : 2024-05-01 Epub Date: 2023-11-06 DOI:10.1097/CEJ.0000000000000851

Xin Wang, Qingqing Yu, Xue Bai, Xinyu Li, Yanli Sun, Xiaoxiang Peng, Ronglan Zhao

{"title":"The role of the purinergic ligand-gated ion channel 7 receptor in common digestive system cancers.","authors":"Xin Wang, Qingqing Yu, Xue Bai, Xinyu Li, Yanli Sun, Xiaoxiang Peng, Ronglan Zhao","doi":"10.1097/CEJ.0000000000000851","DOIUrl":null,"url":null,"abstract":"<p><p>The incidence of digestive malignancies has increased in recent years, including colorectal cancer (CRC), hepatocellular carcinoma (HCC) and pancreatic cancer. Advanced stages of these cancers are prone to metastasis, which seriously reduce the standard of living of patients and lead to decline in the survival rate of patients. So far there are no good specific drugs to stop this phenomenon. It is very important and urgent to find new biomarkers and therapeutic targets. Purinergic ligand-gated ion channel 7 receptor (P2X7R) is ATP-gated and nonselective ion channel receptor involved in many inflammatory processes and cancer progression. P2X7R is present in many cancer cells and promotes or inhibits cancer development through signal transduction. Studies have presented that P2X7R plays a role in the proliferation and migration of digestive system cancers, such as CRC, HCC and pancreatic cancer. Therefore, P2X7R may serve as a biomarker or therapeutic target for digestive system cancers. This paper describes the structure and function of P2X7R, and mainly reviews the research progress on the role of P2X7R in CRC, HCC and pancreatic cancer.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":"271-281"},"PeriodicalIF":2.1000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer Prevention","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CEJ.0000000000000851","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The incidence of digestive malignancies has increased in recent years, including colorectal cancer (CRC), hepatocellular carcinoma (HCC) and pancreatic cancer. Advanced stages of these cancers are prone to metastasis, which seriously reduce the standard of living of patients and lead to decline in the survival rate of patients. So far there are no good specific drugs to stop this phenomenon. It is very important and urgent to find new biomarkers and therapeutic targets. Purinergic ligand-gated ion channel 7 receptor (P2X7R) is ATP-gated and nonselective ion channel receptor involved in many inflammatory processes and cancer progression. P2X7R is present in many cancer cells and promotes or inhibits cancer development through signal transduction. Studies have presented that P2X7R plays a role in the proliferation and migration of digestive system cancers, such as CRC, HCC and pancreatic cancer. Therefore, P2X7R may serve as a biomarker or therapeutic target for digestive system cancers. This paper describes the structure and function of P2X7R, and mainly reviews the research progress on the role of P2X7R in CRC, HCC and pancreatic cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

嘌呤能配体门控离子通道7受体在常见消化系统癌症中的作用。

近年来，消化系统恶性肿瘤的发病率有所上升，包括结直肠癌（CRC）、肝细胞癌（HCC）和癌症。这些癌症的晚期容易发生转移，严重降低了患者的生活水平，导致患者的生存率下降。到目前为止，还没有好的特效药来阻止这种现象。寻找新的生物标志物和治疗靶点是非常重要和紧迫的。嘌呤能连接物门控离子通道7受体（P2X7R）是一种ATP-门控非选择性离子通道受体，参与许多炎症过程和癌症进展。P2X7R存在于许多癌症细胞中，并通过信号传导促进或抑制癌症的发展。研究表明，P2X7R在消化系统癌症（如CRC、HCC和癌症）的增殖和迁移中发挥作用。因此，P2X7R可以作为消化系统癌症的生物标志物或治疗靶点。本文介绍了P2X7R的结构和功能，重点综述了P2X7R在结直肠癌、肝癌和癌症中的作用研究进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

European Journal of Cancer Prevention 医学-肿瘤学

CiteScore

4.10

自引率

4.20%

发文量

审稿时长

1 months

期刊介绍： European Journal of Cancer Prevention aims to promote an increased awareness of all aspects of cancer prevention and to stimulate new ideas and innovations. The Journal has a wide-ranging scope, covering such aspects as descriptive and metabolic epidemiology, histopathology, genetics, biochemistry, molecular biology, microbiology, clinical medicine, intervention trials and public education, basic laboratory studies and special group studies. Although affiliated to a European organization, the journal addresses issues of international importance.